Reply

Affiliations

¹ Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
² Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Comment

Konstantinos Papamichael et al. Clin Gastroenterol Hepatol. 2018 Apr.

. 2018 Apr;16(4):598-599.

doi: 10.1016/j.cgh.2017.12.030.

¹ Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
² Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

No abstract available

Comment on

Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, Cheifetz AS. Papamichael K, et al. Clin Gastroenterol Hepatol. 2017 Oct;15(10):1580-1588.e3. doi: 10.1016/j.cgh.2017.03.031. Epub 2017 Mar 30. Clin Gastroenterol Hepatol. 2017. PMID: 28365486 Free PMC article.
Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive.
Steenholdt C. Steenholdt C. Clin Gastroenterol Hepatol. 2018 Apr;16(4):597-598. doi: 10.1016/j.cgh.2017.11.033. Clin Gastroenterol Hepatol. 2018. PMID: 29555230 No abstract available.